Patents Assigned to Albert Einstein College of Medicine
  • TRANSDERMAL DELIVERY FORMULATIONS
    Publication number: 20220142913
    Abstract: A transdermal formulation for the delivery of a nitric oxide booster or nitric oxide precursor to a subject is provided. The formulation can be applied to the treatment of various diseases or conditions by enhancing systemic level of nitric oxide.
    Type: Application
    Filed: January 26, 2022
    Publication date: May 12, 2022
    Applicant: Albert Einstein College of Medicine
    Inventor: Joel M. Friedman
  • TRANSDERMAL DELIVERY FORMULATIONS
    Publication number: 20220142947
    Abstract: A transdermal formulation for the delivery of a nitric oxide booster or nitric oxide precursor to a subject is provided. The formulation can be applied to the treatment of various diseases or conditions by enhancing systemic level of nitric oxide.
    Type: Application
    Filed: December 30, 2021
    Publication date: May 12, 2022
    Applicant: Albert Einstein College of Medicine
    Inventor: Joel M. Friedman
  • TREATMENT OF CANCER USING RECALL ANTIGENS DELIVERED BY ATTENUATED BACTERIA
    Publication number: 20220125901
    Abstract: Methods, pharmaceutical compositions and vaccines comprising an attenuated bacteria that expresses a recall antigen are disclosed for treatment of cancer.
    Type: Application
    Filed: November 16, 2021
    Publication date: April 28, 2022
    Applicant: ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
    Inventor: Claudia Gravekamp
  • Methods and compositions for treating and preventing arthritis
    Patent number: 11298327
    Abstract: Methods and formulations are provided for treating or preventing arthritis, in particular osteoarthritis, where the formulation to be administered to a subject for treating or preventing arthritis comprises carvacrol, curcumin, epigallocatechin-3-gallate and oligomeric procyanidins.
    Type: Grant
    Filed: September 11, 2020
    Date of Patent: April 12, 2022
    Assignee: Albert Einstein College of Medicine
    Inventors: Hui B. Sun, Daniel J. Leong, Neil J. Cobelli, David M. Hirsh, John A. Hardin, Karen E. Sperling, Sun J. Kim, David C. Spray, Chandan Guha, Marwa Choudhury
  • STEM-LOOP COMPOSITIONS AND METHODS FOR INHIBITING VASCULAR ENDOTHELIAL GROWTN FACTOR
    Publication number: 20220098591
    Abstract: The application discloses methods and compositions for inhibiting functions associated with vascular endothelial growth factor-A (VEGF-A). The methods and compositions may involve the use of pan-variant specific aptamers for binding to VEGF-A, and preventing or reducing association of VEGF-A with Flt-1, KDR, or Nrp-1. The methods and compositions may include one or more aptamers that bind to receptor binding face of VEGF-A. The methods and compositions may include one or more aptamers that bind to a receptor binding domain of VEGF-A. The application further provides anti-VEGF-A aptamers for the treatment of ocular diseases or disorders. In some cases, the anti-VEGF-A aptamers may have a stem-loop secondary structure.
    Type: Application
    Filed: January 10, 2020
    Publication date: March 31, 2022
    Applicants: DRIVE THERAPEUTICS LLC, ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
    Inventors: Carl ERICKSON, Christopher P. RUSCONI, Matthew LEVY, Keith E. MAIER, Sarah E. THACKER, Derek PARKS
  • Broad spectrum viral inhibitor
    Patent number: 11279728
    Abstract: Compounds and methods for treating viral infections and reducing viral multiplication, including flaviviruses. Provided is a derivative of a compound or a pharmaceutical salt thereof, wherein the compound comprises a 3?,4-didehydroribose.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: March 22, 2022
    Assignees: Albert Einstein College of Medicine, The Penn State Research Foundation
    Inventors: Steven C. Almo, Tyler Grove, Anthony Gizzi, Craig E. Cameron, James J. Arnold
  • MICROBIAL HYPERSWARMERS AND USES THEREOF
    Publication number: 20220080002
    Abstract: Bacterial hyperswarmers are disclosed for treatment, prevention and diagnosis of conditions such as intestinal inflammation.
    Type: Application
    Filed: October 8, 2021
    Publication date: March 17, 2022
    Applicant: Albert Einstein College of Medicine
    Inventors: Sridhar Mani, Libusha Kelly, Hao Li
  • HHLA2 as a novel inhibitor of human immune system and uses thereof
    Patent number: 11261253
    Abstract: Provided are methods of treating an autoimmune disease in a subject, or of suppressing transplant rejection in a subject, or of treating a cancer in a subject, as well as compositions therefor.
    Type: Grant
    Filed: September 5, 2018
    Date of Patent: March 1, 2022
    Assignee: Albert Einstein College of Medicine
    Inventor: Xingxing Zang
  • Monoclonal antibodies and cocktails for treatment of Ebola infections
    Patent number: 11254732
    Abstract: Described herein are compositions and methods for the prevention and treatment of ebolavirus infection. In certain embodiments of the present invention, monoclonal antibodies substantially similar to those described herein, as well as affinity matured variants thereof, alone or in combination, provide therapeutic efficacy in a patient against multiple species of ebolavirus.
    Type: Grant
    Filed: June 9, 2020
    Date of Patent: February 22, 2022
    Assignees: MAPP BIOPHARMACEUTICAL, INC., ALBERT EINSTEIN COLLEGE OF MEDICINE, ADIMAB, LLC
    Inventors: Zachary A. Bornholdt, Larry Zeitlin, Kartik Chandran, Anna Wec, Laura Walker
  • Monoclonal antibodies and cocktails for treatment of Ebola infections
    Patent number: 11242379
    Abstract: Described herein are compositions and methods for the prevention and treatment of ebolavirus infection. In certain embodiments of the present invention, monoclonal antibodies substantially similar to those described herein, as well as affinity matured variants thereof, alone or in combination, provide therapeutic efficacy in a patient against multiple species of ebolavirus.
    Type: Grant
    Filed: June 9, 2020
    Date of Patent: February 8, 2022
    Assignees: MAPP BIOPHARMACEUTICAL, INC., ALBERT EINSTEIN COLLEGE OF MEDICINE, ADIMAB, LLC
    Inventors: Zachary A. Bornholdt, Larry Zeitlin, Kartik Chandran, Anna Wec, Laura Walker
  • Monoclonal antibodies and cocktails for treatment of Ebola infections
    Patent number: 11242378
    Abstract: Described herein are compositions and methods for the prevention and treatment of ebolavirus infection. In certain embodiments of the present invention, monoclonal antibodies substantially, similar to those described herein, as well as affinity matured variants thereof, alone or in combination, provide therapeutic efficacy in a patient against multiple species of ebolavirus.
    Type: Grant
    Filed: June 9, 2020
    Date of Patent: February 8, 2022
    Assignees: MAPP BIOPHARMACEUTICAL, INC., ALBERT EINSTEIN COLLEGE OF MEDICINE, ADIMAB, LLC
    Inventors: Zachary A. Bornholdt, Larry Zeitlin, Kartik Chandran, Anna Wec, Laura Walker
  • SMALL MOLECULE INHIBITION OF SULFOTRANSFERASE SULT1A3
    Publication number: 20220024876
    Abstract: Provided herein are small molecule compounds and methods inhibiting human sulfotransferase 1A3 (SULT1A3) using these small molecule compounds. Methods of manufacturing and treatment are also disclosed.
    Type: Application
    Filed: December 10, 2019
    Publication date: January 27, 2022
    Applicants: University of Pittsburgh - Of the Commonwealth System of Higher Education, Albert Einstein College of Medicine
    Inventors: Alexander Deiters, Kristie E. Darrah, Mary Frances Cacace, Ian Cook, Thomas Leyh, Ting Wang
  • Methods for high throughput receptor:ligand identification
    Patent number: 11226339
    Abstract: Methods and systems for high-throughput Identification of receptor:ligand interactions are provided. Throughout this application various publications are referred to in parentheses. Full citations for these references may be found at the end of the specification. The disclosures of these publications, and all patents, patent application publications and books referred to herein, are hereby incorporated by reference in their entirety into the subject application to more fully describe the art to which the subject invention pertains.
    Type: Grant
    Filed: July 25, 2018
    Date of Patent: January 18, 2022
    Assignee: ALBERT EINSTEIN COLLEGE OF MEDICINE
    Inventors: Steven C. Almo, Ronald D. Seidel, III, Brandan S. Hillerich, Sarah C. Garrett-Thomson, James D. Love
  • Treatment of cancer using recall antigens delivered by attenuated bacteria
    Patent number: 11213577
    Abstract: Methods, pharmaceutical compositions and vaccines comprising an attenuated bacteria that expresses a recall antigen are disclosed for treatment of cancer.
    Type: Grant
    Filed: April 26, 2016
    Date of Patent: January 4, 2022
    Assignee: Albert Einstein College of Medicine, Inc.
    Inventor: Claudia Gravekamp
  • DNA METHYLTRANSFERASE 1 TRANSITION STATE STRUCTURE AND USES THEREOF
    Publication number: 20210407627
    Abstract: Methods and systems for obtaining inhibitors of human DNA methyltransferase 1 (DNMT1) are disclosed where the methods involve designing compounds that resemble the DNMT1 transition state.
    Type: Application
    Filed: September 3, 2021
    Publication date: December 30, 2021
    Applicant: Albert Einstein College of Medicine
    Inventors: Vern L. Schramm, Quan Du, Zhen Wang
  • TMIGD2 AND ITS DERIVATIVES AS BLOCKERS OR BINDERS OF CANCER-EXPRESSED HHLA2 FOR IMMUNOTHERAPIES
    Publication number: 20210388052
    Abstract: Provided are methods of treating an HHLA2-bearing tumor in a subject with a fusion protein comprising an IgV-like domain of a TMIGD2 sufficient to treat the HHLA2-bearing tumor. A fusion protein comprising an IgV-like domain of a TMIGD2 and related compositions and encoding nucleic acids are also provided.
    Type: Application
    Filed: January 4, 2021
    Publication date: December 16, 2021
    Applicant: ALBERT EINSTEIN COLLEGE OF MEDICINE
    Inventors: Xingxing Zang, Jordan M. Chinai, Murali Janakiram, Steven C. Almo, Andras Fiser
  • ANTAGONIST ANTIBODIES AGAINST HUMAN IMMUNE CHECKPOINT CEACAM1 (CD66a) AND FORMULATIONS, KITS, AND METHODS OF USE THEREOF
    Publication number: 20210380687
    Abstract: Provided are isolated antibodies and antigen-binding fragments thereof that specifically bind CEACAM1, including the IgV domain of CEACAM1, as well as pharmaceutical formulations, kits, and methods of use thereof.
    Type: Application
    Filed: December 20, 2019
    Publication date: December 9, 2021
    Applicant: ALBERT EINSTEIN COLLEGE OF MEDICINE
    Inventor: Xingxing ZANG
  • FIDGETIN-LIKE 2 SIRNA-ENHANCED POLOXAMER-BASED HYDROGEL FOR WOUND HEALING
    Publication number: 20210353824
    Abstract: Methods and compositions for reducing a ratio of collagen III to collagen I in wounded skin, treating wounds and accelerating healing is provided with a surfactant polymer dressing comprising FL2 siRNA, collagen and a poloxamer.
    Type: Application
    Filed: October 23, 2019
    Publication date: November 18, 2021
    Applicants: ALBERT EINSTEIN COLLEGE OF MEDICINE, MICROCURE, INC.
    Inventors: David James SHARP, Brian O'ROURKE, Adam Hildyard KRAMER
  • Synthetic antibodies to BAX and uses thereof
    Patent number: 11174308
    Abstract: Synthetic fragment antigen-binding (Fab) antibodies are disclosed that bind to an N-terminal activation site of BCL-2-associated X-protein (BAX) and inhibit BAX activation. Also disclosed are methods of using the Fabs for measuring inactive monomeric BAX levels, screening for small molecules that bind to an N-terminal activation site of BAX, inhibiting apoptotic cell death, and predicting the ability of a cancer therapy to promote apoptotic cell death.
    Type: Grant
    Filed: August 10, 2020
    Date of Patent: November 16, 2021
    Assignees: ALBERT EINSTEIN COLLEGE OF MEDICINE, INC., THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO
    Inventors: Evripidis Gavathiotis, Jonathan R. Lai, Sachdev Sidhu
  • Phosphocofilin: cofilin co-localization intensity as a predictor of metastatic recurrence
    Patent number: 11169154
    Abstract: Methods and products are provided for determining if a subject having a tumor is at risk of metastasis of the tumor. Specifically, the methods comprise detecting phosphorylated cofilin, and both phosphorylated and non-phosphorylated cofilin; quantifying the phosphorylated cofilin, and the total of phosphorylated and nonphosphorylated cofilin; and determining if a subject having the tumor is likely to experience metastasis of the tumor, based on the ratio of the amount of detected phosphorylated cofilin:total amount of phosphorylated and non-phosphorylated cofilin detected. Further disclosed are the types of tumor metastases that can be determined using the methods provided.
    Type: Grant
    Filed: July 24, 2018
    Date of Patent: November 9, 2021
    Assignees: ALBERT EINSTEIN COLLEGE OF MEDICINE, KING'S COLLEGE LONDON
    Inventors: John Condeelis, Tony Tsz-Cheong Ng, Gregory Weitsman